Rivaroxaban reduced the risk of composite endpoint in ACS, but increased risk of major bleeding and intracranial hemorrhage, though not fatal bleeding.
Conversion to and from dabigatran to other anticoagulants is depending on the creatinine clearance, longer period for washout is needed as clearance drops.
Difficulties in onset and maintenance of sleep as well as feeling of non restorative sleep were associated with increase in risk of myocardial infarction.
Rivaroxaban is an anticoagulant that acts by selective direct inhibition of factor Xa. It is the latest oral anticoagulant to be approved by US FDA, after dabigatran.
Neurodevelopmental problems post d-TGA repair Children who would never have survived to adulthood due to D-transposition of great arteries are now able to grow well into adulthood, thanks